← Back to headlines
Regeneron Exceeds Q1 Estimates Driven by Dupixent Sales
Regeneron Pharmaceuticals reported first-quarter earnings that topped analyst estimates, largely attributed to the strong momentum of its drug Dupixent.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Nvidia Reports Record Second-Quarter Earnings Driven by Surging AI Demand
44m ago
Universal Studios Japan Announces Nearly $2 Billion Expansion Project
1h ago
Nvidia Earnings Fuel Broad Market Rally Ahead of Jackson Hole Symposium
1h ago
Mixed Corporate Earnings Drive Market Movements as Burlington Slides
1h ago